Table 2.
Baseline demographics, disease characteristics, and treatment parameters of the study population
| Overall (N = 192) | Same day (N = 95) | Next day (N = 97) | p valuea | |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Male | 62 (32.3) | 31 (32.6) | 31 (32.0) | 0.921 |
| Female | 130 (67.7) | 64 (67.4) | 66 (68.0) | |
| Race, n (%) | ||||
| White or Caucasian | 155 (80.7) | 77 (81.1) | 78 (80.4) | 0.180 |
| Black or African American | 21 (10.9) | 13 (13.7) | 8 (8.2) | |
| Other | 16 (8.3) | 5 (5.3) | 11 (11.3) | |
| Age, years | ||||
| Mean ± SD | 58.9 ± 12.7 | 57.5 ± 12.7 | 60.4 ± 12.7 | 0.114 |
| ECOG performance status, n (%) | ||||
| 0 | 105 (54.7) | 58 (61.1) | 47 (48.5) | 0.191 |
| 1 | 82 (42.7) | 35 (36.8) | 47 (48.5) | |
| 2 | 5 (2.6) | 2 (2.1) | 3 (3.1) | |
| BSA, m2 | ||||
| Mean ± SD | 1.86 ± 0.24 | 1.87 ± 0.24 | 1.86 ± 0.25 | 0.739 |
| BMI, kg/m2 | ||||
| Mean ± SD | 27.34 ± 5.76 | 27.07 ± 5.57 | 27.61 ± 5.95 | 0.522 |
| Primary tumor type, n (%) | ||||
| Breast cancer | 62 (32.3) | 32 (33.7) | 30 (30.9) | 0.963 |
| Non-small cell lung cancer | 61 (31.8) | 29 (30.5) | 32 (33.0) | |
| Non-Hodgkin’s lymphoma | 58 (30.2) | 29 (30.5) | 29 (29.9) | |
| Ovarian cancer | 11 (5.7) | 5 (5.3) | 6 (6.2) | |
| Tumor stageb, n (%) | ||||
| Non-advanced | 99 (51.6) | 51 (53.7) | 48 (49.5) | 0.560 |
| Advanced | 93 (48.4) | 44 (46.3) | 49 (50.5) | |
| Chemotherapy regimen, n (%) | ||||
| Intermediate risk of FNc | 119 (62.0) | 58 (61.1) | 61 (62.9) | 0.794 |
| High risk of FNd | 73 (38.0) | 37 (38.9) | 36 (37.1) | |
BMI body mass index, BSA body surface area, ECOG eastern cooperative oncology group, FN febrile neutropenia, SD standard deviation
aTwo-sample t test was used to test differences for continuous variables, and Chi-square test or Fisher’s exact test (if expected cell frequency was <5) were used to test differences for categorical variables between same-day and next-day patients. No multiplicity adjustment was used and p values should be considered nominal
bStages I, II, and III or “limited” were classified as non-advanced; stage IV or “extensive” were classified as advanced
cRegimens with an intermediate risk (10–20 %) of FN included: 21-day R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) and 21-day carboplatin and docetaxel
dRegimens with a high risk (>20 %) of FN included: 21-day TAC (docetaxel, doxorubicin, and cyclophosphamide) and 21-day topotecan